Status:
COMPLETED
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
Lead Sponsor:
GlaxoSmithKline
Conditions:
Social Anxiety Disorder
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Primary diagnosis of Social Anxiety Disorder.
- Willing to restrict alcohol to a limited intake.
- Exclusion criteria:
- History of schizophrenia, schizoaffective disorder or a bipolar disorder.
- Left-handed.
- Suffer from claustrophobia.
- Any reason why subject could not go into the fMRI, for example have metal implants.
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00332046
Start Date
January 1 2006
Last Update
October 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
La Jolla, California, United States, 92093